Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

Trypsin activity governs increased susceptibility to pancreatitis in mice expressing human PRSS1R122H.

Gui F, Zhang Y, Wan J, Zhan X, Yao Y, Li Y, Haddock AN, Shi J, Guo J, Chen J, Zhu X, Edenfield BH, Zhuang L, Hu C, Wang Y, Mukhopadhyay D, Radisky ES, Zhang L, Lugea A, Pandol SJ, Bi Y, Ji B.

J Clin Invest. 2019 Sep 24. pii: 130172. doi: 10.1172/JCI130172. [Epub ahead of print]

2.

Directed evolution of the metalloproteinase inhibitor TIMP-1 reveals that its N- and C-terminal domains cooperate in matrix metalloproteinase recognition.

Raeeszadeh-Sarmazdeh M, Greene KA, Sankaran B, Downey GP, Radisky DC, Radisky ES.

J Biol Chem. 2019 Jun 14;294(24):9476-9488. doi: 10.1074/jbc.RA119.008321. Epub 2019 Apr 30.

PMID:
31040180
3.

Novel Pathogenic PRSS1 Variant p.Glu190Lys in a Case of Chronic Pancreatitis.

Jancsó Z, Oracz G, Kujko AA, Kolodziejczyk E, Radisky ES, Rygiel AM, Sahin-Tóth M.

Front Genet. 2019 Feb 6;10:46. doi: 10.3389/fgene.2019.00046. eCollection 2019.

4.

Bad Tumors Made Worse: SPINK1.

Mehner C, Radisky ES.

Front Cell Dev Biol. 2019 Feb 4;7:10. doi: 10.3389/fcell.2019.00010. eCollection 2019. No abstract available.

5.

PRSS3/Mesotrypsin and kallikrein-related peptidase 5 are associated with poor prognosis and contribute to tumor cell invasion and growth in lung adenocarcinoma.

Ma H, Hockla A, Mehner C, Coban M, Papo N, Radisky DC, Radisky ES.

Sci Rep. 2019 Feb 12;9(1):1844. doi: 10.1038/s41598-018-38362-0.

6.

Disulfide engineering of human Kunitz-type serine protease inhibitors enhances proteolytic stability and target affinity toward mesotrypsin.

Cohen I, Coban M, Shahar A, Sankaran B, Hockla A, Lacham S, Caulfield TR, Radisky ES, Papo N.

J Biol Chem. 2019 Mar 29;294(13):5105-5120. doi: 10.1074/jbc.RA118.007292. Epub 2019 Jan 30.

PMID:
30700553
7.

Mapping protein selectivity landscapes using multi-target selective screening and next-generation sequencing of combinatorial libraries.

Naftaly S, Cohen I, Shahar A, Hockla A, Radisky ES, Papo N.

Nat Commun. 2018 Sep 26;9(1):3935. doi: 10.1038/s41467-018-06403-x.

8.

Combinatorial engineering of N-TIMP2 variants that selectively inhibit MMP9 and MMP14 function in the cell.

Arkadash V, Radisky ES, Papo N.

Oncotarget. 2018 Aug 10;9(62):32036-32053. doi: 10.18632/oncotarget.25885. eCollection 2018 Aug 10.

9.

A potent, proteolysis-resistant inhibitor of kallikrein-related peptidase 6 (KLK6) for cancer therapy, developed by combinatorial engineering.

Sananes A, Cohen I, Shahar A, Hockla A, De Vita E, Miller AK, Radisky ES, Papo N.

J Biol Chem. 2018 Aug 17;293(33):12663-12680. doi: 10.1074/jbc.RA117.000871. Epub 2018 Jun 22.

10.

Pre-equilibrium competitive library screening for tuning inhibitor association rate and specificity toward serine proteases.

Cohen I, Naftaly S, Ben-Zeev E, Hockla A, Radisky ES, Papo N.

Biochem J. 2018 Apr 16;475(7):1335-1352. doi: 10.1042/BCJ20180070.

11.

Converting a broad matrix metalloproteinase family inhibitor into a specific inhibitor of MMP-9 and MMP-14.

Shirian J, Arkadash V, Cohen I, Sapir T, Radisky ES, Papo N, Shifman JM.

FEBS Lett. 2018 Apr;592(7):1122-1134. doi: 10.1002/1873-3468.13016. Epub 2018 Mar 12.

12.

EGFR as a prognostic biomarker and therapeutic target in ovarian cancer: evaluation of patient cohort and literature review.

Mehner C, Oberg AL, Goergen KM, Kalli KR, Maurer MJ, Nassar A, Goode EL, Keeney GL, Jatoi A, Radisky DC, Radisky ES.

Genes Cancer. 2017 May;8(5-6):589-599. doi: 10.18632/genesandcancer.142.

13.

Therapeutic Potential of Matrix Metalloproteinase Inhibition in Breast Cancer.

Radisky ES, Raeeszadeh-Sarmazdeh M, Radisky DC.

J Cell Biochem. 2017 Nov;118(11):3531-3548. doi: 10.1002/jcb.26185. Epub 2017 Jul 17. Review.

14.

Small molecule inhibitors of mesotrypsin from a structure-based docking screen.

Kayode O, Huang Z, Soares AS, Caulfield TR, Dong Z, Bode AM, Radisky ES.

PLoS One. 2017 May 2;12(5):e0176694. doi: 10.1371/journal.pone.0176694. eCollection 2017.

15.

Development of High Affinity and High Specificity Inhibitors of Matrix Metalloproteinase 14 through Computational Design and Directed Evolution.

Arkadash V, Yosef G, Shirian J, Cohen I, Horev Y, Grossman M, Sagi I, Radisky ES, Shifman JM, Papo N.

J Biol Chem. 2017 Feb 24;292(8):3481-3495. doi: 10.1074/jbc.M116.756718. Epub 2017 Jan 13.

16.

An Acrobatic Substrate Metamorphosis Reveals a Requirement for Substrate Conformational Dynamics in Trypsin Proteolysis.

Kayode O, Wang R, Pendlebury DF, Cohen I, Henin RD, Hockla A, Soares AS, Papo N, Caulfield TR, Radisky ES.

J Biol Chem. 2016 Dec 16;291(51):26304-26319. Epub 2016 Nov 3.

17.

MYC Is a Crucial Mediator of TGFβ-Induced Invasion in Basal Breast Cancer.

Cichon MA, Moruzzi ME, Shqau TA, Miller E, Mehner C, Ethier SP, Copland JA, Radisky ES, Radisky DC.

Cancer Res. 2016 Jun 15;76(12):3520-30. doi: 10.1158/0008-5472.CAN-15-3465. Epub 2016 Apr 13.

18.

Combinatorial protein engineering of proteolytically resistant mesotrypsin inhibitors as candidates for cancer therapy.

Cohen I, Kayode O, Hockla A, Sankaran B, Radisky DC, Radisky ES, Papo N.

Biochem J. 2016 May 15;473(10):1329-41. doi: 10.1042/BJ20151410. Epub 2016 Mar 8.

19.

Tumor cell expression of MMP3 as a prognostic factor for poor survival in pancreatic, pulmonary, and mammary carcinoma.

Mehner C, Miller E, Nassar A, Bamlet WR, Radisky ES, Radisky DC.

Genes Cancer. 2015 Nov;6(11-12):480-9.

20.

Serine protease inhibitor Kazal type 1 (SPINK1) drives proliferation and anoikis resistance in a subset of ovarian cancers.

Mehner C, Oberg AL, Kalli KR, Nassar A, Hockla A, Pendlebury D, Cichon MA, Goergen KM, Maurer MJ, Goode EL, Keeney GL, Jatoi A, Sahin-Tóth M, Copland JA, Radisky DC, Radisky ES.

Oncotarget. 2015 Nov 3;6(34):35737-54. doi: 10.18632/oncotarget.5927.

21.

Mesotrypsin Has Evolved Four Unique Residues to Cleave Trypsin Inhibitors as Substrates.

Alloy AP, Kayode O, Wang R, Hockla A, Soares AS, Radisky ES.

J Biol Chem. 2015 Aug 28;290(35):21523-35. doi: 10.1074/jbc.M115.662429. Epub 2015 Jul 14.

22.

Matrix metalloproteinases as breast cancer drivers and therapeutic targets.

Radisky ES, Radisky DC.

Front Biosci (Landmark Ed). 2015 Jun 1;20:1144-63. Review.

23.

Sequence and conformational specificity in substrate recognition: several human Kunitz protease inhibitor domains are specific substrates of mesotrypsin.

Pendlebury D, Wang R, Henin RD, Hockla A, Soares AS, Madden BJ, Kazanov MD, Radisky ES.

J Biol Chem. 2014 Nov 21;289(47):32783-97. doi: 10.1074/jbc.M114.609560. Epub 2014 Oct 9.

24.

Tyrosine sulfation of human trypsin steers S2' subsite selectivity towards basic amino acids.

Szabó A, Salameh MA, Ludwig M, Radisky ES, Sahin-Tóth M.

PLoS One. 2014 Jul 10;9(7):e102063. doi: 10.1371/journal.pone.0102063. eCollection 2014.

25.

Tumor cell-derived MMP3 orchestrates Rac1b and tissue alterations that promote pancreatic adenocarcinoma.

Mehner C, Miller E, Khauv D, Nassar A, Oberg AL, Bamlet WR, Zhang L, Waldmann J, Radisky ES, Crawford HC, Radisky DC.

Mol Cancer Res. 2014 Oct;12(10):1430-9. doi: 10.1158/1541-7786.MCR-13-0557-T. Epub 2014 May 21.

26.
27.

Zymogen activation confers thermodynamic stability on a key peptide bond and protects human cationic trypsin from degradation.

Szabó A, Radisky ES, Sahin-Tóth M.

J Biol Chem. 2014 Feb 21;289(8):4753-61. doi: 10.1074/jbc.M113.538884. Epub 2014 Jan 8.

28.

Matrix metalloproteinase-10/TIMP-2 structure and analyses define conserved core interactions and diverse exosite interactions in MMP/TIMP complexes.

Batra J, Soares AS, Mehner C, Radisky ES.

PLoS One. 2013 Sep 20;8(9):e75836. doi: 10.1371/journal.pone.0075836. eCollection 2013.

29.

Biochemical and structural insights into mesotrypsin: an unusual human trypsin.

Salameh MA, Radisky ES.

Int J Biochem Mol Biol. 2013 Sep 13;4(3):129-39. Review.

30.

TIMP-1 attenuates blood-brain barrier permeability in mice with acute liver failure.

Chen F, Radisky ES, Das P, Batra J, Hata T, Hori T, Baine AM, Gardner L, Yue MY, Bu G, del Zoppo G, Patel TC, Nguyen JH.

J Cereb Blood Flow Metab. 2013 Jul;33(7):1041-9. doi: 10.1038/jcbfm.2013.45. Epub 2013 Mar 27.

31.

PRSS3/mesotrypsin in prostate cancer progression: implications for translational medicine.

Radisky ES.

Asian J Androl. 2013 Jul;15(4):439-40. doi: 10.1038/aja.2013.14. Epub 2013 Mar 18. No abstract available.

32.

Long-range electrostatic complementarity governs substrate recognition by human chymotrypsin C, a key regulator of digestive enzyme activation.

Batra J, Szabó A, Caulfield TR, Soares AS, Sahin-Tóth M, Radisky ES.

J Biol Chem. 2013 Apr 5;288(14):9848-59. doi: 10.1074/jbc.M113.457382. Epub 2013 Feb 19.

33.

PRSS3/mesotrypsin is a therapeutic target for metastatic prostate cancer.

Hockla A, Miller E, Salameh MA, Copland JA, Radisky DC, Radisky ES.

Mol Cancer Res. 2012 Dec;10(12):1555-66. doi: 10.1158/1541-7786.MCR-12-0314.

34.

PEGylation extends circulation half-life while preserving in vitro and in vivo activity of tissue inhibitor of metalloproteinases-1 (TIMP-1).

Batra J, Robinson J, Mehner C, Hockla A, Miller E, Radisky DC, Radisky ES.

PLoS One. 2012;7(11):e50028. doi: 10.1371/journal.pone.0050028. Epub 2012 Nov 20.

35.

Matrix metalloproteinase induction of Rac1b, a key effector of lung cancer progression.

Stallings-Mann ML, Waldmann J, Zhang Y, Miller E, Gauthier ML, Visscher DW, Downey GP, Radisky ES, Fields AP, Radisky DC.

Sci Transl Med. 2012 Jul 11;4(142):142ra95. doi: 10.1126/scitranslmed.3004062.

36.

Presence versus absence of hydrogen bond donor Tyr-39 influences interactions of cationic trypsin and mesotrypsin with protein protease inhibitors.

Salameh MA, Soares AS, Alloy A, Radisky ES.

Protein Sci. 2012 Aug;21(8):1103-12. doi: 10.1002/pro.2097. Epub 2012 Jun 25.

37.

MYC suppresses cancer metastasis by direct transcriptional silencing of αv and β3 integrin subunits.

Liu H, Radisky DC, Yang D, Xu R, Radisky ES, Bissell MJ, Bishop JM.

Nat Cell Biol. 2012 May 13;14(6):567-74. doi: 10.1038/ncb2491.

38.

Matrix metalloproteinase-10 is required for lung cancer stem cell maintenance, tumor initiation and metastatic potential.

Justilien V, Regala RP, Tseng IC, Walsh MP, Batra J, Radisky ES, Murray NR, Fields AP.

PLoS One. 2012;7(4):e35040. doi: 10.1371/journal.pone.0035040. Epub 2012 Apr 24.

39.

Matrix metalloproteinase-10 (MMP-10) interaction with tissue inhibitors of metalloproteinases TIMP-1 and TIMP-2: binding studies and crystal structure.

Batra J, Robinson J, Soares AS, Fields AP, Radisky DC, Radisky ES.

J Biol Chem. 2012 May 4;287(19):15935-46. doi: 10.1074/jbc.M112.341156. Epub 2012 Mar 16.

40.

The P(2)' residue is a key determinant of mesotrypsin specificity: engineering a high-affinity inhibitor with anticancer activity.

Salameh MA, Soares AS, Hockla A, Radisky DC, Radisky ES.

Biochem J. 2011 Nov 15;440(1):95-105. doi: 10.1042/BJ20110788.

41.

Identifying the stroma as a critical player in radiation-induced mammary tumor development.

Cichon MA, Radisky ES, Radisky DC.

Cancer Cell. 2011 May 17;19(5):571-2. doi: 10.1016/j.ccr.2011.05.001. No abstract available.

42.

High affinity small protein inhibitors of human chymotrypsin C (CTRC) selected by phage display reveal unusual preference for P4' acidic residues.

Szabó A, Héja D, Szakács D, Zboray K, Kékesi KA, Radisky ES, Sahin-Tóth M, Pál G.

J Biol Chem. 2011 Jun 24;286(25):22535-45. doi: 10.1074/jbc.M111.235754. Epub 2011 Apr 22.

43.

Determinants of affinity and proteolytic stability in interactions of Kunitz family protease inhibitors with mesotrypsin.

Salameh MA, Soares AS, Navaneetham D, Sinha D, Walsh PN, Radisky ES.

J Biol Chem. 2010 Nov 19;285(47):36884-96. doi: 10.1074/jbc.M110.171348. Epub 2010 Sep 22.

44.

Cathepsin D: Regulation in mammary gland remodeling, misregulation in breast cancer.

Radisky ES.

Cancer Biol Ther. 2010 Sep 1;10(5):467-70. Epub 2010 Sep 30. No abstract available.

45.

Matrix metalloproteinase-induced epithelial-mesenchymal transition in breast cancer.

Radisky ES, Radisky DC.

J Mammary Gland Biol Neoplasia. 2010 Jun;15(2):201-12. doi: 10.1007/s10911-010-9177-x. Epub 2010 May 5. Review.

46.

The 19-amino acid insertion in the tumor-associated splice isoform Rac1b confers specific binding to p120 catenin.

Orlichenko L, Geyer R, Yanagisawa M, Khauv D, Radisky ES, Anastasiadis PZ, Radisky DC.

J Biol Chem. 2010 Jun 18;285(25):19153-61. doi: 10.1074/jbc.M109.099382. Epub 2010 Apr 15.

47.

Mesotrypsin promotes malignant growth of breast cancer cells through shedding of CD109.

Hockla A, Radisky DC, Radisky ES.

Breast Cancer Res Treat. 2010 Nov;124(1):27-38. doi: 10.1007/s10549-009-0699-0. Epub 2009 Dec 25.

48.

The amyloid precursor protein/protease nexin 2 Kunitz inhibitor domain is a highly specific substrate of mesotrypsin.

Salameh MA, Robinson JL, Navaneetham D, Sinha D, Madden BJ, Walsh PN, Radisky ES.

J Biol Chem. 2010 Jan 15;285(3):1939-49. doi: 10.1074/jbc.M109.057216. Epub 2009 Nov 17.

49.

Homology with vesicle fusion mediator syntaxin-1a predicts determinants of epimorphin/syntaxin-2 function in mammary epithelial morphogenesis.

Chen CS, Nelson CM, Khauv D, Bennett S, Radisky ES, Hirai Y, Bissell MJ, Radisky DC.

J Biol Chem. 2009 Mar 13;284(11):6877-84. doi: 10.1074/jbc.M805908200. Epub 2009 Jan 7.

50.

Structural basis for accelerated cleavage of bovine pancreatic trypsin inhibitor (BPTI) by human mesotrypsin.

Salameh MA, Soares AS, Hockla A, Radisky ES.

J Biol Chem. 2008 Feb 15;283(7):4115-23. Epub 2007 Dec 12.

Supplemental Content

Loading ...
Support Center